Lei Jieping, Huang Ke, Pan Jun, Li Wei, Niu Hongtao, Ren Xiaoxia, Dong Fen, Li Yong, Li Baicun, Jia Cunbo, Yang Ting, Wang Chen
Department of Clinical Research and Data Management, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, PR China.
National Center for Respiratory Diseases, Beijing, PR China.
ERJ Open Res. 2023 Apr 24;9(2). doi: 10.1183/23120541.00597-2022. eCollection 2023 Mar.
COPD is the most prevalent chronic respiratory disease in China. It is estimated that there is a large, as-yet undetected, high-risk population who will develop in COPD in future.
In this context, a nationwide COPD screening programme was launched on 9 October 2021. This multistage sequential screening programme incorporates a previously validated questionnaire ( COPD Screening Questionnaire) and pre- and post-bronchodilator spirometry to target the COPD high-risk population. The programme plans to recruit 800 000 participants (eligible age 35-75 years) from 160 districts or counties of 31 provinces, autonomous regions or municipalities across China. The filtered COPD high-risk population and early-detected COPD patients will receive integrated management and be followed-up for ≥1 year.
This is the first large-scale prospective study to determine the net benefit of mass screening for COPD in China. Whether the smoking cessation rate, morbidity, mortality and health status of individuals at high risk of COPD could be improved along with this systematic screening programme will be observed and validated. Moreover, the diagnostic accuracy, cost-effectiveness and superiority of the screening programme will also be assessed and discussed. The programme marks a remarkable achievement in the management of chronic respiratory disease in China.
慢性阻塞性肺疾病（COPD）是中国最常见的慢性呼吸道疾病。据估计，未来将有大量尚未被发现的高危人群会患上COPD。
在此背景下，2021年10月9日启动了一项全国性的COPD筛查项目。这个多阶段序贯筛查项目采用了先前经验证的问卷（COPD筛查问卷）以及支气管扩张剂使用前后的肺功能测定，以针对COPD高危人群。该项目计划从中国31个省、自治区或直辖市的160个区或县招募80万名参与者（ eligible age 35 - 75岁）。筛选出的COPD高危人群和早期发现的COPD患者将接受综合管理并随访≥1年。
这是在中国确定COPD大规模筛查净效益的第一项大规模前瞻性研究。将观察并验证随着这个系统筛查项目，COPD高危个体的戒烟率、发病率、死亡率和健康状况是否能够得到改善。此外，还将评估和讨论筛查项目的诊断准确性、成本效益和优势。该项目标志着中国慢性呼吸道疾病管理取得了显著成就。
